Visit morningcommutepodcast.com/endometrial2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts on endometrial cancer discuss patient selection, toxicities, toxicity management, and how new therapies are entering into the clinical domain with increasing frequency.

In this episode, our faculty, Dr. Charu Aggarwal and Beth Sandy, MSN, CRNP, FAPO, discuss biomarker testing, first-line treatment decisions, including some of the latest clinical data from the anaplastic lymphoma kinase (ALK) trials, and real-world strategies to manage toxicities in patients with ALK-positive NSCLC.

Visit https://suitehome.atpointofcare.com/library/2694.01/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss what clinicians need to know about optimizing treatment strategies for their patients with multiple myeloma. They explore approaches to bridging therapy to improve efficacy and reduce toxicity, evidence-based principles for sequencing B-cell maturation antigen (BCMA)-targeted agents, and how to navigate the challenge of prior BCMA exposure to improve patient outcomes. Visit https://suitehome.atpointofcare.com/library/2676.13/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, explore shifting CAR T-cell therapy into earlier lines of treatment for patients with relapsed/refractory disease, and discuss treatment updates recently presented at ASH 2024 and the 2025 Tandem Meetings. ** Visit https://suitehome.atpointofcare.com/library/2676.11/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit**

In this episode, Staying the Course in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Marissa Marti-Smith talk about the importance of shared decision making and patient education. What do your patients need to know about the latest data on toxicities and toxicity management to help them better adhere to their treatment regimen?

Visit https://suitehome.atpointofcare.com/library/2685.03/page/0?subdomain=breastcancer to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

Visit MorningCommutePodcast.com/NSCLC3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations. At the time this podcast was recorded, cemiplimab was pending approval.

In this episode, Mapping the Pathway in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Dr. Reshma Mahtani take a deeper dive into the phosphatidylinositol 3-kinase (PI3K) and AKT inhibitors for the treatment of metastatic hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This episode will help you better understand these treatments as well as the causes of treatment resistance. Visit https://suitehome.atpointofcare.com/library/2685.02/page/0?subdomain=breastcancer to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

Visit http://morningcommutepodcast.com/MultipleMyeloma1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Rvi Vij and Dr. Thomas Martin will discuss treatment of multiple myeloma in patients who have relapsed. Most of these patients are on maintenance therapy, so how do you select the right regimen for them? The good news is that there are many from which to choose.